Common prescription medications can affect how long people live
Live Forever Club - 11-Oct-2024Metformin (HR 1.01, CI 0.95–1.07) had a neutral effect on mortality
Join the club for FREE to access the whole archive and other member benefits.
Assistant Professor at University of Lausanne
Alejandro Ocampo obtained his PhD in 2012 from the University of Miami for his work under the supervision of Antoni Barrientos on the role of mitochondria in neurodegenerative proteinopathies and aging. Between 2013 and 2017, he performed a post-doctoral training with Juan Carlos Izpisua-Belmonte at the Salk Institute for Biological Studies in La Jolla, California. During his post-doctoral training at the Salk, he developed a novel technology to prevent the transmission of mitochondrial diseases and demonstrated the amelioration of age-associated hallmarks by partial cellular reprogramming. In August 2018, he joined the Department of Pharmacology and Toxicology as Assistant Professor and will continue his work on aging, cellular reprogramming and mitochondrial diseases.
Visit website: https://www.ocampolab.com/
See also: University of Lausanne (UNIL) - Public research university.
Details last updated 11-Feb-2021
13-Jun-2024 to 16-Jun-2024
Event gathering Global Longevity and Rejuvenation community in Dublin by LEV Foundation (Dublin, Ireland)
10-May-2024 to 11-May-2024
The leading networking event for rejuvenation startups, longevity investors and translational researchers by Forever Healthy Foundation
01-Oct-2024
World longevity congress organised by José Luis Cordeiro (Madrid, Spain, FREE)
Developing rejuvenation gene therapies based on partial reprogramming by Yamanaka factors
Metformin (HR 1.01, CI 0.95–1.07) had a neutral effect on mortality
This breakthrough offers hope for combating age-related cognitive decline
A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials
Viagra, cholesterol meds & estrogen replacements linked to longevity, but further research needed
Planning to test its therapies in dogs next year, with human treatments expected in the near future
Another company enters the cellular reprogramming race - hopefully at least one will cross the finishing line
Previous attempts resulted in younger cells but the mice developed tumours. Salk Institute Salk ...